Reuters (10/12, Satija) reports that the FDA “said on Wednesday there was a shortage of Adderall [amphetamine and dextroamphetamine], a treatment for” patients with “attention deficit hyperactivity disorder, following intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd.” While “other manufacturers continue to produce amphetamine mixed salts, but there is not sufficient supply to continue to meet U.S. market demand through those producers, the U.S. health regulator said.”
ABC News (10/12, Pezenik, Salzman, Egan) reports that “Dr. Anish Dube from the American Psychiatric Association told ABC News” that “while stopping Adderall is generally not life-threatening, rebound symptoms, including inattention, hyperactivity and impulsivity, may return and be distressing.”
Related Links:
— “U.S. FDA warns of ADHD drug Adderall shortage on Teva manufacturing delays ” Bhanvi Satija, Reuters, October 12, 2022